Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Phase 3 Clinical Trial for the Treatment of Chronic Motor Deficit from Traumatic Brain Injury (TBI)

Next Previous
Trial Profile

A Global Phase 3 Clinical Trial for the Treatment of Chronic Motor Deficit from Traumatic Brain Injury (TBI)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandefitemcel (Primary)
  • Indications Traumatic brain injuries
  • Focus Registrational; Therapeutic Use
  • Sponsors SanBio

Most Recent Events

  • 14 Sep 2020 According to a SanBio media release, the SanBio Group have postponed this global Phase 3 clinical trial for the TBI program of SB623, it had planned to commence this fiscal year to the next or subsequent fiscal years.
  • 17 Apr 2019 New trial record
  • 16 Apr 2019 According to a SanBio media release, the company plans to initiate this trial by the end of fiscal year ending January 31, 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top